Secondary Logo

Journal Logo

Research articles: COVID-19

Coronavirus disease 2019 infection in patients with recent cardiac surgery: does chronic anticoagulant therapy have a protective effect?

Inama, Giuseppea; Dodi, Claudioa; Provini, Martinoa; Bossoni, Enzoa; Inama, Lorenzab; Balzarini, Laurac; Mancini, Chiarac; Ramponi, Sarac; Marvisi, Maurizioc

Author Information
Journal of Cardiovascular Medicine: October 2020 - Volume 21 - Issue 10 - p 765-771
doi: 10.2459/JCM.0000000000001066
  • Free

Abstract

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than 1.5 million people worldwide, causing over 100 000 deaths in the first 3 months of 2020.1,2

Although the estimated fatality rate because of SARS-CoV-2 disease [(known as coronavirus disease 2019 (COVID-19)] is about 3%, the number of deaths registered in recent weeks suggest a distinctly higher mortality, especially in elderly people.3,4 The disease is transmitted not only mainly through respiratory droplets but also through contact and has a period of incubation ranging from 3 to 7–9 days.5–7 The first phase of infection is characterized by minor respiratory symptoms, fever, dry cough, shortage of breath and myalgia. In 15–20% of cases, this is followed by interstitial pneumonia with progressive immunomediated respiratory insufficiency, which may lead to acute respiratory distress syndrome (ARDS) requiring intensive treatment and mechanical ventilation.

As yet, no vaccine against the virus exists nor do we have any direct therapy for COVID-19 disease. Pharmacological treatments with antivirals or monoclonal antibodies that are already used in other diseases have been proposed in order to reduce viral replication, at least in the initial phase.8–14 In-vitro studies showed that the SARS-CoV-2 virus seems to disappear on contact with high concentrations of enoxaparin sodium, an anticoagulant widely used to prevent venous thromboembolism.15 This finding has prompted Chinese researchers to undertake clinical studies in which a high dosage of the active principle is administered to patients affected by COVID-19; the preliminary results, while promising, remain to be validated in controlled clinical trials.16–18

Enoxaparin is a low-molecular-weight heparin (LMWH) which exerts a marked antithrombotic activity. Owing to its efficacious anticoagulant effect, it is used in the prophylaxis of venous thromboembolism, particularly in patients undergoing surgery or at risk of developing thrombi.19–21 More recently, some evidence has emerged of the role of heparin in the case of COVID-19 infection, leading the WHO to recommend the subcutaneous administration of LMWH for preventing venous thromboembolism and improving the clinical management of hospitalized patients with SARS.22 Indeed, the molecular structure of heparin is similar to that of the site of the cell wall to which SARS-CoV-2 adheres before penetrating into the cell. On this basis, many clinical studies on the use of enoxaparin in patients affected by COVID-19 have been initiated worldwide.23

It is currently established that patients aged above 70 years with multiple comorbidities are most vulnerable to COVID-19 and may have a more complicated clinical course, leading to death in up to 80% of cases.24,25 Most often, this patient subset has recently undergone a cardiac procedure [e.g. valve replacement or coronary artery bypass graft (CABG) surgery, percutaneous coronary intervention (PCI) with stenting, device implantation] and is prescribed with cardiovascular pharmacological therapy, not devoid of possible drug interactions.

The aim of the present retrospective observational study was to evaluate the impact, clinical course and complications of coronavirus infection in a patient population who had recently undergone a cardiac procedure or suffered from severe heart failure, and who were inpatients in a cardiac rehabilitation department for clinical and functional recovery.

Methods

The research was entirely carried out at the Department of Cardiology and Cardiac Rehabilitation of the Istituto Figlie di San Camillo di Cremona (Italy). Between 1 February and 15 March 2020, 35 patients (16 men, mean age 78 years, range 56–90 years) were admitted to our Department for cardiac rehabilitation. All patients admitted to our Rehabilitation Department had been transferred on the seventh to eighth day after a cardiac procedure or for severe heart failure. All patients presented more than five risk factors or comorbidities (Fig. 1). On 19 February 2020, the first case of COVID-19 was reported in Codogno, a municipality located 20 km from our hospital, and COVID-19 was rapidly spreading throughout the surrounding territory.

Fig. 1
Fig. 1:
Comorbidities of the study population. AF, atrial fibrillation; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; EF, ejection fraction.

During hospitalization, 10 patients (group 1: 4 men; mean age 81 years, range 65–89) developed a clinical picture of respiratory infection and were preventively placed in isolation. Among these patients, four had undergone aortic valve replacement, two pacemaker implantation, two mitral valve replacement, one CABG, and one PCI. Nine patients were on chronic oral anticoagulant therapy (with warfarin in three, edoxaban in two, rivaroxaban in two, dabigatran in one, and apixaban in one), whereas one patient was on acetylsalicylic acid (ASA) and clopidogrel (Fig. 2). Because of persisting symptoms of fever and coughing, nasopharyngeal swab tests were performed on the 10 symptomatic patients and proved positive COVID-19 infection. A chest computed tomography scan also revealed interstitial--alveolar pneumonia with frosted glass appearance in all 10 patients (Fig. 3), who were then transferred to the COVID-19 dedicated area of our hospital.

Fig. 2
Fig. 2:
Flowchart and clinical course of the study population. Api, apixaban; ASA, acetylsalicylic acid; Dab, dabigatran; Edo, edoxaban; F, female; M, male; Riva, rivaroxaban.
Fig. 3
Fig. 3:
Chest computed tomography: extensive bilateral ‘frosted glass’ areas with peripheral micronodules.

The remaining 25 patients (group 2: 9 men; mean age 76 years, range 56–90) were found to be COVID-19-negative (Fig. 2).

Results

During hospitalization, our patients received azithromycin 750 mg/day for 5 days and hydroxychloroquine 400 mg/day for 7 days, in addition to their ongoing cardiovascular pharmacological therapy. To treat mild oxygen desaturation, four patients underwent O2 therapy with a Venturi mask for 2–3 days, which was gradually tapered off following improvement. Neither QT prolongation nor ventricular arrhythmia was observed on ECG after hydroxychloroquine administration. Among group 1 patients, only an 85-year-old woman on ASA with clopidogrel was transferred to the ICU for mechanical ventilation because of worsening of her respiratory condition. During ICU stay, her condition deteriorated, she suffered irreversible cardiorespiratory arrest and died. The remaining nine patients recovered and were discharged from the COVID-19 unit; swab testing for SARS-CoV-2 infection before discharge proved negative (Fig. 2).

Overall, among the 10 COVID-19-positive patients, the nine patients who were on chronic anticoagulant therapy had a favorable course. Despite the presence of major comorbidities, the picture of interstitial--alveolar pneumonia improved without requiring either invasive or noninvasive ventilation. The only patient who died was not on chronic anticoagulation, but only received antiplatelet therapy.

Discussion

Although COVID-19 infection can have a mild clinical course and may be completely asymptomatic, many patients present with symptoms, such as fever, headache, diffuse pain, rhinitis, conjunctivitis, cough, diarrhea or vomiting, and anosmia.26 In the initial phase of the disease, individuals with a weaker immune response can develop an abnormal acute inflammatory response, causing more serious symptoms with an increased concentration of proinflammatory cytokines [i.e. tumor necrosis factor-α (TNF-α) and interleukins (IL)]. IL-6, in particular, induces the expression of tissue factor on mononuclear cells, which activates the coagulation cascade and promotes the generation of thrombin. TNF-α and IL-1, on the other hand, represent the main mediators capable of suppressing the endogenous anticoagulant pathways.27–31 In severe COVID-19, patients may experience the cytokine storm syndrome characterized by a hyperinflammatory response with a marked increase in the indexes of inflammation and D-dimer levels.32,33 This systemic hyper-inflammation results in inflammatory lymphocytic and monocytic infiltration of the lung. Monocytes differentiate in macrophages, which give rise to destruction of functional lung tissue, on the one hand, and to vigorous processes of ‘repair-proliferation’, on the other. These processes involve progressive fibrosis and, in the vascular endothelium, progression toward an obliterating micro-angiopathy, with promotion of thrombus formation in arterioles and great vessels (Fig. 4).34,35

Fig. 4
Fig. 4:
Patterns and pathogenesis of corona virus disease-19. (a) Structure and transmission of COVID-19: the virus enters the body, displaying a certain affinity to the alveolar tissue. (b) Current understanding of key events in COVID-19 pathogenesis: after intratracheal inoculation, the virus infects bronchial epithelial cells through dipeptidyl peptidase 4 before spreading into the lung parenchymal cells, including type I and type II alveolar pneumocytes and endothelial cells. IL, interleukin; MIF, macrophage migration inhibitory factor; PAF, platelet-activating factor; TNF, tumor necrosis factor. Modified with permission from Arabi et al. 34 COVID-19, corona virus disease 19.

Recently, several reports described excessive activation of the coagulation cascade in COVID-19 patients. In 94 patients with confirmed SARS-CoV-2 infection, antithrombin III was found to be lower than in 40 healthy volunteers (P < 0.001). By contrast, D-dimer, fibrin, and its degradation products (FDP) and fibrinogen were elevated.36 This observation was confirmed in 183 consecutive patients hospitalized for COVID-19, in whom mortality was strongly influenced by elevated D-dimer levels and FDP (P < 0.05).17 Noteworthy, 71.4% of the patients who died, as opposed to 0.6% of those who survived, presented criteria for diagnosis of disseminated intravascular coagulation.17 Moreover, it was observed that anticoagulation with LMWH for at least 7 days improved prognosis at 28 days, at least in patients with sepsis-induced coagulopathy (score ≥4; 40 vs. 64.2%, P = 0.029) or with a circulating D-dimer level six-fold higher than the upper limit of normal (32.8 vs. 52.4%, P = 0.017).17 Thus, coagulation activation seems to be particularly marked in COVID-17 patients, with consequent worsening of their prognosis.

Recent autopsy findings have documented the presence of interstitial or alveolar infiltrates containing macrophages, microthrombotic formations, and microvascular alterations with pulmonary thromboembolism (Fig. 5), making adequate ventilation challenging in patients with COVID-19 pneumonia associated with acute respiratory distress. Excessive activation of coagulation can give rise to disseminated intravascular coagulation and anoxia because of microvessel thrombosis, ultimately leading to acute pulmonary insufficiency, multiorgan failure, septic shock, and death. Moreover, it has recently been hypothesized that affected patients may present a pattern of pulmonary embolism even in the absence of risk factors and of deep vein thrombosis.37

Fig. 5
Fig. 5:
Chest computed tomography. Pulmonary thromboembolism in corona virus disease-19 pneumonia: partial thrombus at the level of the bifurcation of the right lower lobar branch (arrow); multiple bilateral peripheral pulmonary thickening, some still with a partially ‘frosted glass’ appearance, others with substantially complete alveolar occupation. COVID-19, corona virus disease 19.

In severe COVID-19, the early use of anticoagulant therapy has been proposed to improve treatment outcomes and survival. This has prompted Chinese researchers to undertake clinical studies on high-dose enoxaparin administration to COVID-19 patients. In addition, LMWH has been used not only as an anticoagulant but also to exploit its anti-inflammatory effect.15,16 In the early stage of COVID-19, timely supportive therapies should be implemented including antibiotics and hydroxychloroquine. Antiviral drugs with possible side-effects are also currently under clinical evaluation. However, in the event of a sudden hyperinflammatory response, prophylactic LMWH therapy is indicated in most COVID-19 patients in combination with beta-lactams and azithromycin, maximum gastroprotection, and steroid used. LMWH, which possesses both anticoagulant and anti-inflammatory properties, should be administered at a dosage of 50 IU/kg twice daily or, preferably, of 100 IU/kg twice daily if not contraindicated.

High-dose heparin for thromboprophylaxis is routinely administered to COVID-19 patients in the ICU. Interestingly, in our small but selected population, although patients were elderly, suffered from heart disease, and had numerous comorbidities, the fact that they were on chronic anticoagulant treatment seemed to have limited the serious complications of interstitial pneumonia. It may therefore be hypothesized that chronic anticoagulant therapy, which was already ongoing in our patients at the onset of the viral infection, may have a similar effect to that of the targeted heparin therapy administered in the ICU. That is to say, it may act not upon pulmonary alveolar damage, but upon the subsequent coagulation in the pulmonary microvessels, which can dramatically complicate infection because of SARS-CoV-2.

Study limitations

The limitations of this observational study are the small sample size and the lack of a control group, though not uncommon in the initial phase of a pandemic.

Conclusion

COVID-19 has spread rapidly throughout the world, displaying a disproportionately high lethality rate among elderly patients with concomitant cardiovascular, pulmonary, and metabolic diseases.38 As no approved radical therapies exist, every effort is being made to identify an efficacious therapy and to create a vaccine to prevent future infections.24,39 The relatively high mortality of severe COVID-19 is a matter of concern. Although the limited sample size cannot allow definitive conclusions to be drawn from our study, patients who are already on chronic anticoagulant therapy, even if elderly and with multiple comorbidities, seem to have a better prognosis because of a lower risk for progressive obliterative microangiopathy and thrombosis of pulmonary arterioles and large vessels. Further prospective studies are needed to confirm this preliminary observation.

Acknowledgements

Conflicts of interest

There are no conflicts of interest.

References

1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507513.
2. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382:727733.
3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497506.
4. Inciardi RM, Adamo M, Lupi L, et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J 2020; 41:18211829.
5. Holbrook M, Gamble A, Williamson B, Tamin A, Harcourt J. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020; 382:15641567.
6. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382:11991207.
7. Xiang SW, Tan YT, Chia PY, et al. Air, surface, environmental and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA 2020; 323:16101612.
8. Mulangu S, Dodd LE, Davey RT, et al. PALM Consortium Study Team. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019; 381:22932303.
9. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11:222.
10. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30:269271.
11. de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A 2020; 117:67716776.
12. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382:17871799.
13. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382:17081720.
14. Castagné B, Viprey M, Martin J, Schott AM, Cucherat M, Soubrier M. Cardiovascular safety of tocilizumab: a systematic review and network meta-analysis. PLoS One 2019; 14:e0220178.
15. Poterucha TJ, Libby P, Goldhaber SZ. More than an anticoagulant: Do heparins have direct anti-inflammatory effects? Thromb Haemost 2017; 117:437444.
16. Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID-19): a clinical update. Front Med 2020; 14:126135.
17. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18:844847.
18. Poston JT, Patel BK, Davis AM. Management of critically Ill adults with COVID-19. JAMA 2020; doi: 10.1001/jama.2020.4914 [published online ahead of print].
19. Venclauskas L, Llau JV, Jenny JY, Kjaersgaard-Andersen P, Jans Ø. ESA VTE Guidelines Task Force. European guidelines on perioperative venous thromboembolism prophylaxis: day surgery and fast-track surgery. Eur J Anaesthesiol 2018; 35:134138.
20. Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res 2019; 181:7783.
21. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol 2020; 75:29502973.
22. World Health Organization (WHO). Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance. 13 January 2020. Available at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. [Accessed 20 May 2020]
23. Low molecular weight heparin in adult patients with COVID-19. Protocol of the Italian Drug Agency (AIFA). Published online 10 April 2020. Available at: https://www.aifa.gov.it/documents/20142/1123276/Eparine_Basso_Peso_Molecolare_11.04.2020.pf/e30686fb-3f5e-32c9-7c5c-951cc40872f7. [Accessed 20 May 2020]
24. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019. Drug Discov Ther 2020; 14:5860.
25. Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J 2020; 55:2000524.
26. Wang DW, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323:10611069.
27. Wan S, Yi Q, Fan S, et al. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br J Haematol 2020; 189:428437.
28. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020; ciaa248doi: 10.1093/cid/ciaa248 [published online ahead of print].
29. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; e200994doi: 10.1001/jamainternmed.2020.0994 [published online ahead of print, 2020 Mar 13].
30. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395:10331034.
31. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant 2020; 39:405407.
32. Iba T, Di Nisio M, Levy J, et al. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open 2017; 7:e017046.
33. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020; 63:364374.
34. Arabi YM, Balkhy HH, Hayden FG, et al. Middle East respiratory syndrome. N Engl J Med 2017; 376:584594.
35. Levi M, Thachil J, Iba T, Levi JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet 2020; 7:e438e440.
36. Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 2020; 58:11161120.
37. Danzi GB, Loffi M, Galezzi G, Gherbesi E. Acute pulmonary embolism and COVID-19: a random association? Eur Heart J 2020; 41:1858.
38. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; doi: 10.1001/jamacardio.2020.1017 [Epub ahead of print].
39. Perlman S. Another decade, another coronavirus. N Engl J Med 2020; 382:760762.
Keywords:

cardiopulmonary rehabilitation; coronavirus disease 2019; low-molecular-weight heparin; new oral anticoagulants; pneumonia

© 2020 Italian Federation of Cardiology - I.F.C. All rights reserved.